Nemvaleukin alfa preferentially activates CD8-positive cytotoxic T cells and NK cells and reduces the expansion of immunosuppressive Tregs, potentially enhancing the anti-cancer immune effects that are primarily mediated by CD8-positive T cells [23,24]. The gene discussed is CD8A; the disease is cancer.